This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MADD / MAP kinase-activating death domain protein · Western blot design guide
Design a Western Blot for MADD
Source-linked MADD Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-MADD WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
MADD Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~183.3 kDa | |
| Observed band | ~240 kDa | |
| Gel | 5–20% (catalog A02030-1) | |
| Positive control | Duodenum (IHC candidate; verify WB) +4 more | |
| Negative control | Heart muscle (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 8 isoform(s) |
Section 1
Source-Linked MADD Western Blot Protocol Options
The A02030-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human K562, human Hela, human HEL, human RT4, rat brain, mouse brain (catalog A02030-1) |
| Gel % | 5–20% (catalog A02030-1) |
| Load | 30 ug; reducing conditions (catalog A02030-1) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog A02030-1) |
| Membrane | nitrocellulose membrane (catalog A02030-1) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog A02030-1) |
| Primary antibody | A02030-1 · 0.5 μg/mL (catalog A02030-1) |
| Primary incubation | overnight at 4°C (catalog A02030-1) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog A02030-1) |
| Secondary incubation | 1.5 hour at RT (catalog A02030-1) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog A02030-1) |
| Detection | ECL (catalog A02030-1) |
Section 2
What Is the Expected MADD Western Blot Band Size?
MADD is predicted at 183.3 kDa but has an empirical band near 240 kDa; the cause of this difference is not established.
| Band near 240 kDa | Empirical MADD band in whole-cell lysate; the cause of its migration above the predicted mass is unestablished |
| Band near 183.3 kDa | Near the predicted mass; confirm its identity with antibody controls |
| Several discrete bands | Could reflect MADD isoforms, but their migration positions are not supplied |
| Closely spaced doublet | Could reflect isoforms; confirm both bands before assigning them |
💡Expected MADD appearanceMADD has a predicted mass of 183.3 kDa, while antibody QC detects a band near 240 kDa in whole-cell lysates; the cause of the difference is unestablished, so confirm identity with antibody controls.
| Predicted MADD mass | 183.3 kDa is the sequence-based reference; an empirical band appears near 240 kDa |
| Isoforms 1 and 2 | Alternative splicing may change size; their individual masses and migration are unknown |
| Isoforms 3 and 4 | Alternative splicing may change size; their individual masses and migration are unknown |
| Isoforms 5, 6, 7, and 8 | Alternative splicing may change size; their individual masses and migration are unknown |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | The observed MADD band is near 240 kDa despite a predicted mass of 183.3 kDa; the cause is unestablished | Compare with a validated positive lysate and confirm band identity with an independent antibody |
| Band lower than expected | A shorter MADD isoform is possible, but isoform masses are unavailable | Confirm identity with an antibody to another region and check which isoforms are expressed |
| Multiple bands | MADD has eight annotated splice isoforms, though their band positions are unknown | Compare antibodies targeting different regions and assess isoform expression |
| Weak or no signal | MADD expression or recovery from its cytoplasmic and membrane locations may be low | Check a positive-control lysate and assess cytoplasmic and membrane fractions |
| Fragments below expected size | Fragment identity is not established by the supplied features | Use an antibody to another region and compare fresh, protease-protected lysate |
Experiment evidence
Western blot images showing MADD band
A02030-1 · MADD
M02030 · MADD
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for MADD Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for MADD in Western blot, you can use duodenum tissue lysate.
Positive control: Duodenum (IHC candidate; verify WB)
Negative control: Heart muscle (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: MADD is membrane-associated and cytoplasmic, so extraction efficiency may affect its signal in tissue lysates.
HPA tissue expression evidence for MADD
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Duodenum | glandular cells | High | Protein (IHC) | HPA → |
| Gallbladder | glandular cells | High | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Smooth muscle | smooth muscle cells | Not detected | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Low | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Low | Protein (IHC) | HPA → |
| Skeletal muscle | myocytes | Low | Protein (IHC) | HPA → |
Section 3
Advanced MADD Western Blot Tips
Deeper troubleshooting and optimisation questions for MADD, answered from its protein features.
How should MADD band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Can MADD isoforms produce different bands?
Isoforms · Yes. UniProt lists eight isoforms with sequence differences, including deletions at canonical positions 762–804, 885–904, 1291–1311, and 1583–1647. These changes could affect band size or antibody recognition. Use the isoform sequence and antibody epitope when assigning a band.
Check whether the epitope overlaps a region altered in the isoform you want to detect. For example, canonical residues 762–804 are missing from isoforms 4, 5, 6, and 8; residues 885–904 are missing from isoforms 3, 5, 6, and 8. Those coordinates refer to the supplied canonical UniProt sequence.
Check whether the epitope overlaps a region altered in the isoform you want to detect. For example, canonical residues 762–804 are missing from isoforms 4, 5, 6, and 8; residues 885–904 are missing from isoforms 3, 5, 6, and 8. Those coordinates refer to the supplied canonical UniProt sequence.
Which MADD phosphorylation sites should I consider?
PTM · UniProt lists phosphoserine at canonical positions 156, 689, 692, 813, 818, 820, 858, 862, 916, 921, 930, 1059, 1110, 1239, and 1270, plus phosphothreonine at 1061, 1066, and 1237. Check the antibody's target site and numbering convention before interpreting a phospho-specific signal.
No. The 18 listed phosphorylated residues establish modification sites, but do not show that phosphorylation produces a resolvable shift or accounts for the approximately 240 kDa band. Compare matched samples if testing a phosphorylation-dependent change, and interpret mobility separately from phospho-specific signal.
No. The 18 listed phosphorylated residues establish modification sites, but do not show that phosphorylation produces a resolvable shift or accounts for the approximately 240 kDa band. Compare matched samples if testing a phosphorylation-dependent change, and interpret mobility separately from phospho-specific signal.
Does this guide establish induction of MADD?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for MADD?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02030-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should MADD be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why might MADD appear near 240 kDa instead of 183.3 kDa?
Interpretation · 183.3 kDa is the predicted mass, while approximately 240 kDa is the reported apparent band. MADD has eight isoforms and documented phosphorylation, but these features alone do not explain the difference. Confirm the band with an antibody whose epitope is known and compare it with the expected isoform in your sample.
Compare the same assigned band across samples. MADD is reported in both cytoplasm and cell membrane, so keep sample preparation and fraction choice consistent. Its eight isoforms can complicate a total-MADD measurement; record which bands the antibody detects and quantify them consistently.
First compare their sizes with the eight documented isoforms and check whether the antibody epitope is retained in each one. Several isoforms have missing or replaced sequence segments. The supplied features cannot identify every extra band, and phosphorylation sites alone do not establish a visible mobility shift.
Compare the same assigned band across samples. MADD is reported in both cytoplasm and cell membrane, so keep sample preparation and fraction choice consistent. Its eight isoforms can complicate a total-MADD measurement; record which bands the antibody detects and quantify them consistently.
First compare their sizes with the eight documented isoforms and check whether the antibody epitope is retained in each one. Several isoforms have missing or replaced sequence segments. The supplied features cannot identify every extra band, and phosphorylation sites alone do not establish a visible mobility shift.
Boster reagents
MADD Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-MADD Antibody Picoband®
Cat # A02030-1
Real WB data
Anti-DENN Rabbit Monoclonal Antibody
Cat # M02030
Two the supplier antibodies are listed for MADD, both with stated human, mouse, and rat reactivity and WB images. A02030-1 shows a band near 240 kDa versus the expected 183 kDa; M02030 has only a brief HeLa lysate caption.
Which to pick: Choose A02030-1 when its documented K562, HeLa, HEL, RT4, rat brain, or mouse brain conditions match your sample. M02030 is a monoclonal option with a HeLa WB image, but its supplied caption gives no band size or detailed conditions.
Source: BosterBio MADD gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q8WXG6.
- Human Protein Atlas. MADD tissue expression.
- PMC12603207 — target-verified WB comparison
- PMC10515055 — target-verified WB comparison
- PMC3865079 — target-verified WB comparison